No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Specialty Business Services
Linical Co., Ltd., a global contract research organization provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariats; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
www.linical.com/jaNo one on the platform currently holds 2183.T.
No tracked institution reports a position in 2183.T as of their last filing.
No one on the platform has traded 2183.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -17.0% | -3.4% | ||||
| Profit Margin % | -38.4% | -5.2% | 2.0% | |||
| Free Cash Flow Margin % | -17.9% | 5.1% | 7.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $13.0B | +4.8% | $29.70 | $29.70–$29.70 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 2183.TLinical Co., Ltd. | $203.00 | -0.49% | $4.6B | — |
| 177A.TKohjin Bio Co., Ltd. | $836.00 | -0.59% | $4.3B | — |
| 2370.TMEDINET Co., Ltd. | $24.00 | +0.00% | $6.7B | — |
| 3750.TADR120S, Inc. | $836.00 | +0.00% | $7.5B | — |
| 4564.TOncoTherapy Science, Inc. | $23.00 | +4.55% | $9.2B | — |
| 4583.TChiome Bioscience Inc. | $88.00 | +1.15% | $6.4B | — |
| 4594.TBrightPath Biotherapeutics Co., Ltd. | $60.00 | +3.45% | $5.0B | — |
Source: Financial Modeling Prep · peers by sector/industry